Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.76
Bid: 5.02
Ask: 6.50
Change: -0.15 (-2.54%)
Spread: 1.48 (29.482%)
Open: 5.91
High: 0.00
Low: 0.00
Prev. Close: 5.91
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS SUMMARY: Angle revenue up; Synairgen, Bango loss widens

Thu, 29th Sep 2022 20:30

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Angle PLC - Surrey, England-based medical diagnostics company - Pretax loss in the first half of 2022 widens to GBP10.5 million from GBP8.7 million, due to "a planned investment." Revenue rises to GBP419,000 from GBP296,000, "driven by research use sales of the Parsortix system along with an initial contribution from the pharma services business, including both clinical trial services and bespoke assay development." Expects its first FDA clearance to "positively impact all areas" of its business going forward.

----------

Bango PLC - Cambridge-based mobile commerce company - Pretax loss widens to USD1.2 million in the first half of 2022 from USD617,000 a year before. Administrative expenses rise to USD10.4 million from USD9.2 million. Revenue grows to USD10.8 million versus USD9.9 million. Attributes this to its "virtuous circle strategy" and investment in research and development, which continues to generate strong growth. Believes it is well positioned to continue taking market share.

----------

XLMedia PLC - Henley-on-Thames-based digital publisher - Pretax loss widens to USD1.7 million in the first half of 2022 from USD439,000 a year ago. Sales and marketing costs jump to USD16.2 million from USD7.3 million. Revenue rises 48% to USD44.5 million from USD32.2 million. Attributes this to new partnerships throughout the period. Expects full-year adjusted earnings before interest, tax, depreciation, and amortization is broadly in line with the prior year, returning to growth in 2023.

----------

Maintel Holdings PLC - London-based cloud and managed service specialist - Pretax loss in the six months to June 30 dives to GBP575,000 from a profit of GBP3.8 million a year before. Revenue falls 13% to GBP46.7 million from GBP53.5 million. Blames this on hardware supply-chain problems that significantly hurt revenue. Notes that supply chains are not expected to normalise until the second quarter of 2023. Remains confident that it will return to organic growth as global supply chains normalise.

----------

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Pretax loss for the half-year to June 30 shrinks to GBP14.0 million from GBP38.9 million, as research and development expenditure falls to GBP11.1 million from GBP36.9 million. Explains that expenditure on the phase 3 Sprinter trial and manufacturing activities reduced.

----------

Armadale Capital PLC - London-based Africa-focused natural resource projects investor - Pretax loss in the first half of 2022 widens to GBP152,000 from GBP27,000 a year before. Records an unrepeated gain of GBP139,000 in the prior period.

----------

Arc Minerals Ltd - base metals exploration company focused in Africa - Pretax loss in the first half widens to GBP8.5 million from GBP3.6 million a year before. Attributes this to an expense of GBP6.8 million, due to the Zamsort/Handa restructuring, after transferring Zamsort assets and liabilities to Handa Resources Ltd.

----------

Orosur Mining Inc - Toronto-based mineral exploration & development company focused on South America - Net loss for continued operations in the year to May 31 narrows to USD1.4 million from USD1.7 million a year before. Gain on fair value of warrants increases to USD1.6 million from USD627,000. "The handing over of operational control at Anza in late 2021, and a strong balance sheet, have freed up our skilled South American team to examine investment in new projects. The addition of our Ariquemes tin project in Brazil, and of the El Pantano gold/silver project in Argentina have transformed the company into a well-balanced minerals exploration company," Executive Louis Castro comments.

----------

VPC Specialty Lending Investments PLC - invests in asset-backed loans to businesses originated by non-bank lenders - Net asset value as at June 30 falls to 105.51 pence from 114.14p as at December 31. Share price on the same date falls to 83.40p from 92.20p as at December 31. Delivers a total return of negative 4.1%. Blames this on an unpredictable and volatile macroeconomic environment. Declares quarterly dividends totalling 4.00 pence per share. Remains in a period of heightened uncertainty, with inflation still at "worryingly high levels".

----------

Crossword Cybersecurity PLC - Richmond, England-based cybersecurity solutions company - Pretax loss in the first half of 2022 widens to GBP2.3 million from GBP1.5 million a year before. Administrative expenses grow to GBP2.1 million from GBP1.5 million. Revenue grows 85% to GBP1.5 million versus GBP824,923. Attributes this to the integration of three companies with strong underlying Software as a service and services recurring revenue. Projects revenue growth of roughly 75% to GBP4 million in 2022, driven by organic growth and already completed acquisitions.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
25 Jan 2021 19:18

TRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic

TRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic

Read more
20 Jan 2021 21:16

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

Read more
13 Jan 2021 10:24

Synairgen Doses First Patient In Covid-19 Treatment Trial

Synairgen Doses First Patient In Covid-19 Treatment Trial

Read more
11 Jan 2021 20:54

COVID SCIENCE-COVID-19 patients still have symptoms 6 months later; interferon may be helpful treatment after all

By Nancy LapidJan 11 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Half a year later, COVID-19 pat...

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 11:06

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Read more
18 Dec 2020 10:29

Synairgen makes solid progress with Covid-19 treatment

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for patients with Covid-19 on Friday, as well as positive progress on its regulatory path.

Read more
18 Nov 2020 13:59

finnCap Interim Profit More Than Doubles; Chair To Step Down

finnCap Interim Profit More Than Doubles; Chair To Step Down

Read more
13 Nov 2020 14:28

Synairgen surges on positive results for Covid-19 treatment

(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respiratory Medicine, showed positive results in hospitalised patients.

Read more
13 Nov 2020 10:24

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Read more
2 Nov 2020 20:03

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

Read more
15 Oct 2020 11:39

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Read more
14 Oct 2020 18:02

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

Read more
29 Sep 2020 12:14

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Read more
9 Sep 2020 16:04

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.